<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00219219</url>
  </required_header>
  <id_info>
    <org_study_id>CZOL446EIT04</org_study_id>
    <nct_id>NCT00219219</nct_id>
  </id_info>
  <brief_title>Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases</brief_title>
  <official_title>Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Società Italiana di Urologia (SIU)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The present study will give information about the course over time in skeletal-related events&#xD;
      (SRE) in prostate cancer patients with bone metastases treated with zoledronic acid 4 mg&#xD;
      administered as a 15-minute infusion every 4 weeks for a maximum of 15 infusions. The&#xD;
      protocol will enroll patients with recent diagnosis of bone metastases from prostate cancer&#xD;
      who are hormone-refractory, hormone-naïve or still hormone-sensitive, that represent the&#xD;
      entire population of prostate cancer patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date>October 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>occurence of skeletale related events (SREs) over time (time to first SRE,skeletal morbidity rate and proportion of patients experiencing SRE)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone pain</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of analgesic medication and ECOG performance status every three months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone specific alkaline phosphatase, serum N-telopeptide and parathyroid hormone will be evaluated after one month of treatment and then every three months</measure>
  </secondary_outcome>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Patients aged ≥18 years&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Histologically-proven prostate carcinoma&#xD;
&#xD;
          -  ECOG performance status ≤ 2&#xD;
&#xD;
          -  Life expectancy &gt; 6 months&#xD;
&#xD;
          -  Newly diagnosed (≤ 6 months prior to visit 1) bone metastases evidenced by bone scan&#xD;
             or radiograph.&#xD;
&#xD;
          -  Patients on androgen deprivation therapy (medical therapy with LHRH analogues +&#xD;
             antiandrogens or surgical castration) or going to start it&#xD;
&#xD;
          -  Patients with partners of childbearing potential should use a barrier method of&#xD;
             contraception throughout the study&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Patients without a history of metastatic disease to the bone&#xD;
&#xD;
          -  Prior treatment with bisphosphonates&#xD;
&#xD;
          -  SREs prior to visit 2&#xD;
&#xD;
          -  Prior treatment with calcitonin, mithramycin, or gallium nitrate within 2 weeks prior&#xD;
             to baseline&#xD;
&#xD;
          -  Corrected (adjusted for serum albumin - see Appendix 5 for the calculation) serum&#xD;
             calcium concentration &lt; 8.0 mg/dl (2.00 mmol/l)&#xD;
&#xD;
          -  Serum creatinine concentration &gt; 265 micromol/l (3.0 mg/dl) or a calculated creatinine&#xD;
             clearance &lt; 30 ml/minute or serious underlying renal disease or prior renal&#xD;
             transplantation&#xD;
&#xD;
          -  History of other malignant neoplasm within previous five years with exception of&#xD;
             non-melanomatous skin cancer which has been satisfactorily treated&#xD;
&#xD;
          -  Other known concurrent, severe medical disorder jeopardizing the life of the patient&#xD;
             in the immediate future&#xD;
&#xD;
          -  Patients treated with systemic investigational drug(s) and/or device(s) within the&#xD;
             past 30 days or topical investigational drugs within the past 7 days&#xD;
&#xD;
          -  Known hypersensitivity to zoledronic acid or other bisphosphonates&#xD;
&#xD;
          -  History of noncompliance to medical regimens and patients who are considered&#xD;
             potentially unreliable (for example drug or alchohol abusers) or incapable of giving&#xD;
             informed consent as judged by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>April 13, 2015</last_update_submitted>
  <last_update_submitted_qc>April 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>zoledronic acid</keyword>
  <keyword>prostate cancer</keyword>
  <keyword>SRE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

